Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 943-350-8 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Skin sensitisation
Administrative data
- Endpoint:
- skin sensitisation: in vivo (non-LLNA)
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 2005-06-29 to 2005-08-22
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: Complete guideline conform study report available. Study is performed under GLP.
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 005
- Report date:
- 2005
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 406 (Skin Sensitisation)
- GLP compliance:
- yes (incl. QA statement)
- Type of study:
- guinea pig maximisation test
- Justification for non-LLNA method:
- A non-LLNA in vivo study was carried out before the entry into force of amendments to Annexes VII and VIII.
Test material
- Reference substance name:
- Reaction products resulting from the esterification of C18 unsaturated fatty acid with glycerol and glycerol oligomers
- EC Number:
- 943-350-8
- Molecular formula:
- not applicable (UVCB)
- IUPAC Name:
- Reaction products resulting from the esterification of C18 unsaturated fatty acid with glycerol and glycerol oligomers
Constituent 1
- Specific details on test material used for the study:
- - Substance name: OPGE022005
- Purity: approx. 100 %
- Batch No.: HS180505
- Appearance: liquid
- Storage: Light protected at room temperature (range 20 +/- 5°C)
- Stability: Stable under storage conditions
- Stability of test item dilution: Unknown in PEG 300 and in 1:1 (v/v) mixture of FCA/physiological saline
In vivo test system
Test animals
- Species:
- guinea pig
- Strain:
- Dunkin-Hartley
- Sex:
- female
Study design: in vivo (non-LLNA)
Inductionopen allclose all
- Route:
- intradermal and epicutaneous
- Vehicle:
- other: PEG 300
- Concentration / amount:
- Pretest
intradermal injection in one animal:
Day 1: 4 intradermal injections (0.1 mL/site) of a 1:1 (V/V) mixture of Freud's Complete Adjuvant/physiol. saline into the shaved neck
Day 7: intradermal injections (0.1mL/site) were made into the clipped flank of same animal at concentrations A= 100%, B= 75%, C= 50 % of test item. PEG 300 was used for dilutions. Based on the result of the pretest, 100% was selected for intradermal injection in the main study.
Epidermal application in two animals:
Day 1: 4 intradermal injections (0.1 mL/site) of a 1:1 (V/V) mixture of Freud's Complete Adjuvant/physiol. saline into the shaved neck of two guines pigs.
Day 7: both flanks of each animal were clipped and shaved just prior to application. Thereafter, 4 patches of filter paper (3x3 cm) were saturated (about 0.2mL)with the testitem at concetrations D= 100%, E= 75%, F= 50% and G= 25% in PEG 300 and applied to the shaved flanks. Patches were covered by a strip of aluminium foil and firmly secured by elastic plaster. Dressings were removed after an exposure period of 24 hours. Twenty one hours after removal of dressing the application site was depilated with an aproved depilation cream. Approximately 3 hours later (48 hours from the epidermal application) the skin reaction was observed for reactions and a second observation was performed 72 hours later.
Main study:
Based on the results obtained in the pretest studies the following concentrations were selected:
induction: 100%
challenge: 25 %
Challengeopen allclose all
- Route:
- epicutaneous, occlusive
- Vehicle:
- other: PEG 300
- Concentration / amount:
- Pretest
intradermal injection in one animal:
Day 1: 4 intradermal injections (0.1 mL/site) of a 1:1 (V/V) mixture of Freud's Complete Adjuvant/physiol. saline into the shaved neck
Day 7: intradermal injections (0.1mL/site) were made into the clipped flank of same animal at concentrations A= 100%, B= 75%, C= 50 % of test item. PEG 300 was used for dilutions. Based on the result of the pretest, 100% was selected for intradermal injection in the main study.
Epidermal application in two animals:
Day 1: 4 intradermal injections (0.1 mL/site) of a 1:1 (V/V) mixture of Freud's Complete Adjuvant/physiol. saline into the shaved neck of two guines pigs.
Day 7: both flanks of each animal were clipped and shaved just prior to application. Thereafter, 4 patches of filter paper (3x3 cm) were saturated (about 0.2mL)with the testitem at concetrations D= 100%, E= 75%, F= 50% and G= 25% in PEG 300 and applied to the shaved flanks. Patches were covered by a strip of aluminium foil and firmly secured by elastic plaster. Dressings were removed after an exposure period of 24 hours. Twenty one hours after removal of dressing the application site was depilated with an aproved depilation cream. Approximately 3 hours later (48 hours from the epidermal application) the skin reaction was observed for reactions and a second observation was performed 72 hours later.
Main study:
Based on the results obtained in the pretest studies the following concentrations were selected:
induction: 100%
challenge: 25 %
- No. of animals per dose:
- Pretest:
Intradermal incection: one animal
dermal application: two animals
Main test
control group I: 5 animals
treatment group: 10 animals
control group II: 5 animals - Positive control substance(s):
- yes
- Remarks:
- alpha-Hexylcinnamaldehyde
Results and discussion
- Positive control results:
- A study was performed with alpha-Hexylcinnamaldehyde in 15 (10 test and 5 control) male albino DunkinHartley guinea pigs.
Induction intradermal with 10% diluted alpha-Hexylcinnamaldehyde in PEG 300. One week after intradermal induction, epidermal induction with the test item at 10 % in PEG 300 for 48h under occlusion followed.
Two weeks after epidermal induction control and test animals were challenged by epidermal application of test item at 1% and 0.1% in PEG 300 and PEG 300 alone under occlusive dressing.
Two weeks after the first challenge a second challenge was performed in the same way.
Results: No toxic signs were evident in the guinea pigs of the control or test group. 4/10 (at 24h reading) and 1/10 (at 48h reading) test animals showed dicrete/patchy erythema after the first challenge treatment with alpha-Hexylcinnamaldehyde at 1% (w/w) in PEG 300. No skin effect were observed in the test group at 0.1%. No skin effect was observed in the control group treated in the same conditions during the challenge procedure.
7/10 animals (at 24 h reading) and 4/10 animals (at the 48 h reading) showed discrete/patchy erythema after the second challenge treatment with alpha-Hexylcinnamaldehyde at 1% (w/w) in PEG 300. One test animal was noted with the same reaction at the 24- and 48-hour reading when treated with the test item at 0.1%. Based on the above mentioned findings alpha-Hexylcinnamaldehyde at 1% is considered to be a sensitizer.
In vivo (non-LLNA)
Resultsopen allclose all
- Key result
- Reading:
- 1st reading
- Hours after challenge:
- 48
- Group:
- other: control for testing positive control
- Dose level:
- PEG 300 only
- No. with + reactions:
- 0
- Total no. in group:
- 4
- Clinical observations:
- No skin effect observed.
- Remarks on result:
- no indication of skin sensitisation
- Key result
- Reading:
- 1st reading
- Hours after challenge:
- 24
- Group:
- other: control for testing positive control
- Dose level:
- PEG 300 only
- No. with + reactions:
- 0
- Total no. in group:
- 4
- Clinical observations:
- No skin effect observed
- Remarks on result:
- no indication of skin sensitisation
- Key result
- Reading:
- 2nd reading
- Hours after challenge:
- 48
- Group:
- positive control
- Dose level:
- 0.1 % in PEG 300; left caudal flank
- No. with + reactions:
- 1
- Total no. in group:
- 10
- Clinical observations:
- One animal out of 10 showed discrete/patchy erythema after second challenge treatment.
- Key result
- Reading:
- 2nd reading
- Hours after challenge:
- 24
- Group:
- positive control
- Dose level:
- 0.1 % in PEG 300; left caudal flank
- No. with + reactions:
- 1
- Total no. in group:
- 10
- Clinical observations:
- One animal out of 10 showed discrete/patchy erythema after second challenge treatment.
- Key result
- Reading:
- 2nd reading
- Hours after challenge:
- 48
- Group:
- positive control
- Dose level:
- 1 % in PEG 300; left cranial flank
- No. with + reactions:
- 4
- Total no. in group:
- 10
- Clinical observations:
- 4 out of 10 animals showed discrete/patchy erythema after second challenge treatment.
- Key result
- Reading:
- 2nd reading
- Hours after challenge:
- 24
- Group:
- positive control
- Dose level:
- 1 % in PEG 300; left cranial flank
- No. with + reactions:
- 7
- Total no. in group:
- 10
- Clinical observations:
- 7 out of 10 animals showed discrete/patchy erythema after second challenge treatment.
- Key result
- Reading:
- 1st reading
- Hours after challenge:
- 48
- Group:
- positive control
- Dose level:
- 0.1 % in PEG 300; left caudal flank
- No. with + reactions:
- 0
- Total no. in group:
- 10
- Clinical observations:
- No skin effect observed.
- Key result
- Reading:
- 1st reading
- Hours after challenge:
- 24
- Group:
- positive control
- Dose level:
- 0.1 % in PEG 300; left caudal flank
- No. with + reactions:
- 0
- Total no. in group:
- 10
- Clinical observations:
- No skin effect observed.
- Key result
- Reading:
- 1st reading
- Hours after challenge:
- 48
- Group:
- positive control
- Dose level:
- 1 % test item in PEG 300; left cranial flank
- No. with + reactions:
- 1
- Total no. in group:
- 10
- Clinical observations:
- 1 out of 10 animals showed discrete/patchy erythema after first challenge treatment
- Key result
- Reading:
- 1st reading
- Hours after challenge:
- 24
- Group:
- positive control
- Dose level:
- 1% test item in PEG300, left cranial flank
- No. with + reactions:
- 4
- Total no. in group:
- 10
- Clinical observations:
- 4 out of 10 animals showed discrete/patchy erythema after first challenge treatment
- Key result
- Reading:
- 1st reading
- Hours after challenge:
- 24
- Group:
- other: Control group I, Ieft flank
- Dose level:
- 25 % in PEG 300
- No. with + reactions:
- 5
- Total no. in group:
- 5
- Clinical observations:
- Animals showed discrete/patchy erythema after first challenge
- Key result
- Reading:
- 1st reading
- Hours after challenge:
- 48
- Group:
- other: Control group I, left flank
- Dose level:
- 25 % in PEG 300
- No. with + reactions:
- 5
- Total no. in group:
- 5
- Clinical observations:
- Animals showed discrete/patchy erythema after first challenge
- Remarks on result:
- other:
- Key result
- Reading:
- 1st reading
- Hours after challenge:
- 24
- Group:
- other: Control group I
- Dose level:
- PEG 300 only, right flank
- No. with + reactions:
- 0
- Total no. in group:
- 5
- Remarks on result:
- no indication of skin sensitisation
- Key result
- Reading:
- 1st reading
- Hours after challenge:
- 48
- Group:
- other: Control group I
- Dose level:
- PEG 300 only, right flank
- No. with + reactions:
- 0
- Total no. in group:
- 5
- Remarks on result:
- no indication of skin sensitisation
- Key result
- Reading:
- 1st reading
- Hours after challenge:
- 24
- Group:
- test chemical
- Dose level:
- 25 % in PEG 300, left flank
- No. with + reactions:
- 10
- Total no. in group:
- 10
- Clinical observations:
- 10 out of 10 animals showed discrete/patchy erythema after first challenge
- Key result
- Reading:
- 1st reading
- Hours after challenge:
- 48
- Group:
- test chemical
- Dose level:
- 25 % in PEG 300; left flank
- No. with + reactions:
- 9
- Total no. in group:
- 10
- Clinical observations:
- 9 out of 10 animals showed discrete/patchy erythema after first challenge
- Key result
- Reading:
- 1st reading
- Hours after challenge:
- 24
- Group:
- test chemical
- Dose level:
- PEG 300 only; right flank
- No. with + reactions:
- 0
- Total no. in group:
- 10
- Remarks on result:
- no indication of skin sensitisation
- Key result
- Reading:
- 1st reading
- Hours after challenge:
- 48
- Group:
- test chemical
- Dose level:
- PEG 300 only; right flank
- No. with + reactions:
- 0
- Total no. in group:
- 10
- Remarks on result:
- no indication of skin sensitisation
- Key result
- Reading:
- 2nd reading
- Hours after challenge:
- 24
- Group:
- other: Control Group II, right cranial flank
- Dose level:
- test item 15 % in PEG 300; right cranial flank
- No. with + reactions:
- 1
- Total no. in group:
- 5
- Clinical observations:
- Animals showed discrete/patchy erythema after second challenge treatment
- Key result
- Reading:
- 2nd reading
- Hours after challenge:
- 48
- Group:
- other: Control group II, right cranial flank
- Dose level:
- test item 15 % in PEG 300
- No. with + reactions:
- 2
- Total no. in group:
- 5
- Clinical observations:
- Animals showed discrete/patchy erythema after second challenge treatment
- Key result
- Reading:
- 2nd reading
- Hours after challenge:
- 24
- Group:
- other: Control group II, right caudal flank
- Dose level:
- test item 10 % in PEG 300
- No. with + reactions:
- 0
- Total no. in group:
- 5
- Clinical observations:
- no skin effects observed
- Remarks on result:
- no indication of skin sensitisation
- Key result
- Reading:
- 2nd reading
- Hours after challenge:
- 48
- Group:
- other: Control group II, right caudal flank
- Dose level:
- test item 10 % in PEG 300
- No. with + reactions:
- 0
- Total no. in group:
- 5
- Clinical observations:
- No skin effects observed
- Remarks on result:
- no indication of skin sensitisation
- Key result
- Reading:
- 2nd reading
- Hours after challenge:
- 24
- Group:
- other: test group, right cranial flank
- Dose level:
- test item 15 % in PEG 300
- No. with + reactions:
- 4
- Total no. in group:
- 10
- Clinical observations:
- 4 out of 10 animals showed discrete /patchy erythema after the second challenge treatment
- Key result
- Reading:
- 2nd reading
- Hours after challenge:
- 48
- Group:
- other: test group, right cranial flank
- Dose level:
- test item 15 % in PEG 300
- No. with + reactions:
- 5
- Total no. in group:
- 10
- Clinical observations:
- 5 out of 10 animals showed discrete /patchy erythema after the second challenge treatment
- Key result
- Reading:
- 2nd reading
- Hours after challenge:
- 24
- Group:
- other: test group, right caudal flank
- Dose level:
- test item 10 % in PEG 300
- No. with + reactions:
- 0
- Total no. in group:
- 10
- Clinical observations:
- No skin effect observed in this test group and in control group II
- Remarks on result:
- no indication of skin sensitisation
- Key result
- Reading:
- 2nd reading
- Hours after challenge:
- 48
- Group:
- other: test group, right caudal flank
- Dose level:
- test item 10 % in PEG 300
- No. with + reactions:
- 0
- Total no. in group:
- 10
- Clinical observations:
- No skin effect observed in this test group and in control group II
- Remarks on result:
- no indication of skin sensitisation
Applicant's summary and conclusion
- Interpretation of results:
- not sensitising
- Remarks:
- Migrated information Criteria used for interpretation of results: EU
- Conclusions:
- Based on the above mentioned findings in an adjuvant sensitization test in guinea pigs, the test item is considered not to be a sensitizer.
- Executive summary:
In order to asses the coutaneous allergic potential of the test item a Magnusson & Kligman study was performed in 20 guinea pigs according to OECD 406. Based on the results of two separate pretests, for intradermal induction the undiluted test item and an emulsion of Freund's Adjuvannt (FCA/ physiol. saline) was used. For the epidermal induction the undiluted test item was used. The animals of the control group I were intradermally induced with PEG 300 and FCA/ physiol. saline and epidermally induced with PEG 300 under occlusion.
Two weeks after the induction period the challenge was perfomed by dermal application of the test item at 25 % (w/w) in PEG 300 and PEG 300 alone under occlusive dressing. Two weeks after the first challenge a second challenge was perfomed in the same way as previous challenge using the same test group and an additional control group II, a naive skin site and the test item concentrations of 15% and 10 % (w/w) in PEG 300. Coutaneous reactions were evaluated at approximately 24 and 48 hours after removal of the dressing.
Results:
No death occured and no toxic signs were evident in all groups. At the 24 h-reading all (10/10) and at the 48 h-reading nine of ten animals showed discrete /patchy erythema after first challenge treatment with the test item at 25 % (w/w) in PEG 300. The same reaction was noted in all animals of the control I group. No skin effect was observed in the test item and control I group when treated with PEG 300 only. Four (at the 24h-reading) and five (at the 48 h-reading) out of 10 test animals showed again discrete/patchy erythema after a second challenge treatment with the test item at 15 % (w/w) in PEG 300. The same reaction was seen in one (at 24h-reading) and two (at 48 h-reading) out of 5 animals of control group II treated with the test item at 15 % (w/w) in PEG 300. No skin effect was observed in the test and control group when treated with the test item at 10 % (w/w) in PEG 300.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.